Mohs micrographic surgery (MMS) has increasingly become an accepted therapy for melanoma in situ on chronically sun damaged skin (CSDS). However, melanocytes are difficult to locate in frozen material on hematoxylin and eosin. In addition, determining the cut-off between the melanoma and the "atypical melanocytic hyperplasia" in CSDS can be challenging in frozen or formalin-fixed paraffin-embedded sections, with or without immunohistochemistry (IHC). In this article, we report the use of a rapid, 35-minute protocol using microphthalmia-associated transcription factor (MITF) IHC for identifying melanocytes in frozen tissue for its potential use in MMS. In contrast to melanoma antigen recognized by T cells (MART-1), MITF is a nuclear stain, which simplifies identification of melanocytes and quantification of melanocytic parameters. In this study, MITF IHC in frozen sections yielded equivalent melanocyte nuclear diameter and density measurements compared with formalin-fixed paraffin-embedded sections. Nuclear diameter measurements obtained with MITF were similar to that previously reported with MART-1, but the melanocyte density figures were lower. Reliable labeling of melanocytes in frozen sections required the use of diaminobenzidine (DAB) chromogen with Giemsa counterstaining and a buffer devoid of surfactant. Our experience with MITF IHC indicates that it is a dependable immunostain in frozen sections, and may prove to be useful in MMS as an adjunct to hematoxylin and eosin and MART-1 IHC for interpretation of margins for melanoma in situ on CSDS.

Download full-text PDF

Source
http://dx.doi.org/10.1097/dad.0b013e3181bcd94fDOI Listing

Publication Analysis

Top Keywords

mitf ihc
12
frozen sections
12
microphthalmia-associated transcription
8
transcription factor
8
melanoma situ
8
hematoxylin eosin
8
formalin-fixed paraffin-embedded
8
paraffin-embedded sections
8
melanocytes frozen
8
nuclear diameter
8

Similar Publications

Introduction: Microphthalmia Transfactor Family (MiTF) translocation renal cell carcinomas (RCCs) represent a rare subtype of renal cell cancers. They are diagnosed in young patients and have a poor prognosis. The aim of our study was to analyze the clinical and pathological features of patients with MiTF RCC.

View Article and Find Full Text PDF

Primary cutaneous carcinosarcoma (PCCS) is a rare cutaneous biphasic tumour with just 120 cases being reported till date. The epithelial component trichoblastic carcinoma/ malignant trichoblastoma (trichoblastic carcinosarcoma) is even rarer, so is the present case. An eighty years old male patient presented with a rapidly progressing ulceroproliferative nodular growth on the left temporal region.

View Article and Find Full Text PDF

RCC accounts for only 0.1%-0.3% of all kidney tumors and 2%-6% of malignant kidney tumors in children.

View Article and Find Full Text PDF

Background: Sarcoma may show similarities to malignant melanoma in terms of morphologic and immunohistochemical aspects, making it difficult to differentiate between these two neoplasms during the diagnostic process. This systematic review aims to summarize available evidence on cases of sarcoma that were initially diagnosed as melanoma.

Methods: A comprehensive search of the MEDLINE/Pubmed, EMBASE, and SCOPUS databases was conducted through March 2023.

View Article and Find Full Text PDF
Article Synopsis
  • MiT-Renal Cell Carcinoma (RCC) is an aggressive cancer subtype affecting mainly young people, characterized by TFE3, TFEB, or MITF gene translocations, which complicates diagnosis and lacks standard treatment options.
  • Research involved characterizing TFE3-RCC cell lines through immunohistochemistry (IHC) and gene expression, followed by a drug screen identifying several promising therapeutic agents, particularly targeting the PI3K/mTOR pathway and using Mithramycin A.
  • Preclinical studies showed that drugs like NVP-BGT226, Mithramycin A, and the antibody-drug conjugate CDX-011 could be effective therapies for advanced MiT-RCC, either alone or
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!